Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The MDM2 SNP309 G allele is not preferentially amplified in bone and soft tissue tumors.

Mertens, Fredrik LU ; Brosjö, Otte ; Vult von Steyern, Fredrik LU ; Hansén Nord, Karolin LU and Mandahl, Nils LU (2012) In Cancer Genetics 205(9). p.470-473
Abstract
The transcriptional enhancer region in intron 1 of the proto-oncogene MDM2 contains a polymorphic site (SNP309) that may harbor a G or a T nucleotide. Previous studies have shown that the G allele confers a higher affinity for the Sp1 transcription factor, resulting in an increased transcriptional activity of MDM2. A constitutional G allele has also been associated with earlier onset of various cancer types, and studies of sarcomas have shown an enrichment of the G allele in tumors with MDM2 amplification, notably atypical lipomatous tumor (also known as well-differentiated liposarcoma). In the present study, we analyzed the SNP309 genotype in blood samples and tumor tissue from 57 patients with bone or soft tissue tumors showing... (More)
The transcriptional enhancer region in intron 1 of the proto-oncogene MDM2 contains a polymorphic site (SNP309) that may harbor a G or a T nucleotide. Previous studies have shown that the G allele confers a higher affinity for the Sp1 transcription factor, resulting in an increased transcriptional activity of MDM2. A constitutional G allele has also been associated with earlier onset of various cancer types, and studies of sarcomas have shown an enrichment of the G allele in tumors with MDM2 amplification, notably atypical lipomatous tumor (also known as well-differentiated liposarcoma). In the present study, we analyzed the SNP309 genotype in blood samples and tumor tissue from 57 patients with bone or soft tissue tumors showing amplification of MDM2. We did not observe any constitutional enrichment of the G allele. More importantly, there was no preferential amplification of the G allele in tumor tissue from TG heterozygotes. The expression levels of MDM2 messenger RNA were not higher in tumors with amplification of the G allele than in tumors with amplification of the T allele. Thus, we could not find any evidence for a selective advantage of the SNP309 G allele in bone and soft tissue tumors with MDM2 amplification. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Genetics
volume
205
issue
9
pages
470 - 473
publisher
Elsevier
external identifiers
  • wos:000308516900008
  • pmid:22939400
  • scopus:84869748757
  • pmid:22939400
ISSN
2210-7762
DOI
10.1016/j.cancergen.2012.06.001
language
English
LU publication?
yes
id
4c8e57ce-77e8-478f-841a-9804f1731642 (old id 3124526)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22939400?dopt=Abstract
date added to LUP
2016-04-04 08:40:12
date last changed
2022-03-23 02:47:43
@article{4c8e57ce-77e8-478f-841a-9804f1731642,
  abstract     = {{The transcriptional enhancer region in intron 1 of the proto-oncogene MDM2 contains a polymorphic site (SNP309) that may harbor a G or a T nucleotide. Previous studies have shown that the G allele confers a higher affinity for the Sp1 transcription factor, resulting in an increased transcriptional activity of MDM2. A constitutional G allele has also been associated with earlier onset of various cancer types, and studies of sarcomas have shown an enrichment of the G allele in tumors with MDM2 amplification, notably atypical lipomatous tumor (also known as well-differentiated liposarcoma). In the present study, we analyzed the SNP309 genotype in blood samples and tumor tissue from 57 patients with bone or soft tissue tumors showing amplification of MDM2. We did not observe any constitutional enrichment of the G allele. More importantly, there was no preferential amplification of the G allele in tumor tissue from TG heterozygotes. The expression levels of MDM2 messenger RNA were not higher in tumors with amplification of the G allele than in tumors with amplification of the T allele. Thus, we could not find any evidence for a selective advantage of the SNP309 G allele in bone and soft tissue tumors with MDM2 amplification.}},
  author       = {{Mertens, Fredrik and Brosjö, Otte and Vult von Steyern, Fredrik and Hansén Nord, Karolin and Mandahl, Nils}},
  issn         = {{2210-7762}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{470--473}},
  publisher    = {{Elsevier}},
  series       = {{Cancer Genetics}},
  title        = {{The MDM2 SNP309 G allele is not preferentially amplified in bone and soft tissue tumors.}},
  url          = {{http://dx.doi.org/10.1016/j.cancergen.2012.06.001}},
  doi          = {{10.1016/j.cancergen.2012.06.001}},
  volume       = {{205}},
  year         = {{2012}},
}